2026-02-13 14:14:38
That is the new book by Joe Studwell, my podcast with him should be coming out pretty soon. Here is Oliver’s new review. Excerpt:
Botswana is Studwell’s poster child for a successful democratic developmental coalition. (For this reason, it featured heavily in Acemoglu and Robinson’s Why Nations Fail as an example of “inclusive institutions”.)
Under the sound leadership of Seretse Khama, local chiefs were carefully co-opted at independence and the Botswana Democratic Party built up into a genuine national force. Khama also created a capable civil service, initially staffed by remaining Europeans, but gradually Africanized with sterling Batswana talent. This meant that when diamonds were discovered just around independence, the windfall was carefully managed, avoiding the worst effects of Dutch Disease. These mining revenues helped raise Botswana to upper middle-income status, making it the fourth-richest country in continental Africa.
Botswana’s chief failing, in Studwell’s view, was adhering too much to responsible policy orthodoxy—i.e., not enough industrial policy. There was no vision for large-scale industrialization, no coherent plan to create large numbers of factory jobs. Moreover, the political dominance of large cattle owners (Botswana was a society of pastoralists rather than farmers) meant that redistribution was never in the cards. The result is a relatively rich society, but one that is highly unequal.
You will be hearing my views on these issues soon enough. Oliver, of course, writes one of the very best Substacks in all of economics.
The post Oliver Kim reviews *How Africa Works* appeared first on Marginal REVOLUTION.
2026-02-13 08:33:14
There is a new paper by Nick Bostrom with that title:
Developing superintelligence is not like playing Russian roulette; it is more like undergoing risky surgery for a condition that will otherwise prove fatal. We examine optimal timing from a person-affecting stance (and set aside simulation hypotheses and other arcane considerations). Models incorporating safety progress, temporal discounting, quality-of-life differentials, and concave QALY utilities suggest that even high catastrophe probabilities are often worth accepting. Prioritarian weighting further shortens timelines. For many parameter settings, the optimal strategy would involve moving quickly to AGI capability, then pausing briefly before full deployment: swift to harbor, slow to berth. But poorly implemented pauses could do more harm than good.
Via Nabeel.
The post Optimal timing for superintelligence appeared first on Marginal REVOLUTION.
2026-02-13 01:53:21
1. Using Claude Code for academic work.
2. Younger Firms and CEOs Allow More Work from Home.
3. Extractive taxes were indeed a major force behind the French Revolution.
4. How much will “the human touch” persist?
5. “It was one attempt to do so, by Charles Jones of Stanford University, that entertained the negative top rate of -26%. If high earners produce a lot of ideas that help society, then “subsidising the discovery of new ideas through low tax rates may be as effective as redistribution in raising worker welfare”, he writes.” (The Economist)
6. Moral intuitions about love, romance, and reproduction are not Coasean.
7. Do not exercise options unless you have to!
8. I know Paul, he has very high standards.
9. Claims about Mexico’s security posture.
The post Thursday assorted links appeared first on Marginal REVOLUTION.
2026-02-12 20:16:29
I had high hopes and low expectations that the FDA under the new administration would be less paternalistic and more open to medical freedom. Instead, what we are getting is paternalism with different preferences. In particular, the FDA now appears to have a bizarre anti-vaccine fixation, particularly of the mRNA variety (disappointing but not surprising given the leadership of RFK Jr.).
The latest is that the FDA has issued a Refusal-to-File (RTF) letter to Moderna for their mRNA influenza vaccine, mRNA-1010. An RTF means the FDA has determined that the application is so deficient it doesn’t even warrant a review. RTF letters are not unheard of, but they’re rare—especially given that Moderna spent hundreds of millions of dollars running Phase 3 trials enrolling over 43,000 participants based on FDA guidance, and is now being told the (apparently) agreed-upon design was inadequate.
Moderna compared the efficacy of their vaccine to a standard flu vaccine widely used in the United States. The FDA’s stated rationale is that the control arm did not reflect the “best-available standard of care.” In plain English, that appears to mean the comparator should have been one of the ACIP-preferred “enhanced” flu vaccines for adults 65+ (e.g., high-dose/adjuvanted) rather than a standard-dose product.
Out of context, that’s not crazy but it’s also not necessarily wise. There is nothing wrong with having multiple drugs and vaccines, some of which are less effective on average than others. We want a medical armamentarium: different platforms, different supply chains, different side-effect profiles, and more options when one product isn’t available or isn’t a good fit. The mRNA vaccines, for example, can be updated faster than standard vaccines, so having an mRNA option available may produce superior real-world effectiveness even if it were less efficacious in a head-to-head trial.
In context, this looks like the regulatory rules of the game are being changed retroactively—a textbook example of regulatory uncertainty destroying option value. STAT News reports that Vinay Prasad personally handled the letter and overrode staff who were prepared to proceed with review. Moderna took the unusual step of publicly releasing Prasad’s letter—companies almost never do this, suggesting they’ve calculated the reputational risk of publicly fighting the FDA is lower than the cost of acquiescing.
Moreover, the comparator issue was discussed—and seemingly settled—beforehand. Moderna says the FDA agreed with the trial design in April 2024, and as recently as August 2025 suggested it would file the application and address comparator issues during the review process.
Finally, Moderna also provided immunogenicity and safety data from a separate Phase 3 study in adults 65+ comparing mRNA-1010 against a licensed high-dose flu vaccine, just as FDA had requested—yet the application was still refused.
What is most disturbing is not the specifics of this case but the arbitrariness and capriciousness of the process. The EU, Canada, and Australia have all accepted Moderna’s application for review. We may soon see an mRNA flu vaccine available across the developed world but not in the United States—not because it failed on safety or efficacy, but because FDA political leadership decided, after the fact, that the comparator choice they inherited was now unacceptable.
The irony is staggering. Moderna is an American company. Its mRNA platform was developed at record speed with billions in U.S. taxpayer support through Operation Warp Speed — the signature public health achievement of the first Trump administration. The same government that funded the creation of this technology is now dismantling it. In August, HHS canceled $500 million in BARDA contracts for mRNA vaccine development and terminated a separate $590 million contract with Moderna for an avian flu vaccine. Several states have introduced legislation to ban mRNA vaccines. Insanity.
The consequences are already visible. In January, Moderna’s CEO announced the company will no longer invest in new Phase 3 vaccine trials for infectious diseases: “You cannot make a return on investment if you don’t have access to the U.S. market.” Vaccines for Epstein-Barr virus, herpes, and shingles have been shelved. That’s what regulatory roulette buys you: a shrinking pipeline of medical innovation.
An administration that promised medical freedom is delivering medical nationalism: fewer options, less innovation, and a clear signal to every company considering pharmaceutical investment that the rules can change after the game is played. And this isn’t a one-product story. mRNA is a general-purpose platform with spillovers across infectious disease and vaccines for cancer; if the U.S. turns mRNA into a political third rail, the investment, talent, and manufacturing will migrate elsewhere. America built this capability, and we’re now choosing to export it—along with the health benefits.
The post I Regret to Inform You that the FDA is FDAing Again appeared first on Marginal REVOLUTION.
2026-02-12 20:10:35
Hat tip: Logan Dobson.
The post That Was Then/This is Now appeared first on Marginal REVOLUTION.
2026-02-12 16:37:57
Following the removal of 50% of unauthorized immigrants, in the short run average native real wages rise 0.15% nationally, driven by an increase in the capital-labor ratio. In the long run, however, native real wages fall in every state, and by 0.33% nationally, as capital gets decumulated in response to a lower population. Consumer prices in the sectors intensive in unauthorized workers – such as Farming – rise by about 1% relative to the price of the average consumption basket, while most other sectors experience negligible relative price changes.
That research result is from
The post The economics of mass deportation appeared first on Marginal REVOLUTION.
